Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

Cost Drivers Contributing to the Economic Impact of Inflammatory Diseases

July 20th 2023

A panel of experts review the key drivers contributing to the economic impact of inflammatory diseases in the United States.

Humanistic and Economic Impact of Inflammatory Diseases

July 20th 2023

Experts discuss the humanistic and economic impacts that affect patients with inflammatory diseases.

Clinical Overview of Inflammatory Diseases

July 20th 2023

Maia Kayal, MD, MS, and Jonathan Kay, MD, provide a clinical overview of inflammatory diseases and describe comorbid conditions typically seen in patients.

Payer Controls Limiting Semglee Uptake Despite Patient Demand

July 20th 2023

By Laura Joszt

A new analysis finds branded insulin glargine (Lantus) still has a majority of total market volume and new drug starts despite competition from Semglee, an interchangeable biosimilar.

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

July 19th 2023

By Skylar Jeremias

The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.

Biosimilars Can Expand Treatment Access for Traditionally Excluded Communities

July 18th 2023

By Justina Petrullo

Biosimilars may be able to increase treatment access for traditionally excluded communities, especially racial and ethnic minority populations.

Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price

July 17th 2023

By Skylar Jeremias

The list price of Humira (reference adalimumab) has risen so dramatically over time that the list prices for new adalimumab biosimilars are now significantly higher than the original price of the originator, according to a report contextualizing net prices of adalimumab and the role of rebates.

Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment

July 16th 2023

By Skylar Jeremias

Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.

Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?

July 15th 2023

By Deana Ferreri, PhD

A review article sheds light on the growing adalimumab market in the US, including how these products are being priced, strategies companies are using to make their product stand out, and recommendations for policymakers to ensure the accessibility and affordability of these products.

Senator Reintroduces Biosimilar Red Tape Elimination Act

July 14th 2023

By Skylar Jeremias

Senator Mike Lee (R, Utah) reintroduced the Biosimilar Red Tape Elimination Act to Congress. The bill aims to get rid of switching study requirements for companies looking to obtain an interchangeability designation for a biosimilar.